新闻中心
Zennova Pharmaceutical Has Attracted Attention in Investment Summit
来源: | 作者:诺峰药业 | 发布时间: 2020-08-26 | 1125 次浏览 | 分享到:
On August 25, 2020, the "Rushing! Back Waves”-Chengdu Tianfu International Bio-city Financial Service Summit" was held at the Bio-city Cultural Center, Chengdu, Chiina. Mr. Li Yali, the General Manager of Zennova Pharmaceuticals, was invited and gave a presentation talk as one of the featured representative companies in this event.


On August 25, 2020, the
"Rushing! Back Waves”-Chengdu Tianfu International Bio-city Financial Service Summit" was held at the Bio-city Cultural Center, Chengdu, Chiina.  Mr. Li Yali, the General Manager of Zennova Pharmaceuticals, was invited and gave a presentation talk as one of the  featured representative companies in this event.

This event attracted 60 financial institutions and companies to participate in the conference. It is sponsored by the Chengdu High-tech Zone Bio-city Management Committee and Chengdu Venture Capital Association.

Zennova Pharmaceutical is an innovation-driven pharmaceutical company dedicated to the research and development of innovative new drugs and high-barrier complex formulation drugs.  The products under research mainly focus on the fields of ophthalmic, oncology and anti-infectious disease. Zennova’s full-dose forms world-class manufacturing plant is located in the Tianfu International Biological City of Chengdu, China. It is designed and built with America’s cutting-edge pharmaceutical technology and top international quality standards.  All products will sell to  U.S., China, EU markets and other global markets.




(The scene of the meeting, picture source: cover news)


  


Zennova Pharmaceuticals Group has developed its patented
LiquiPuls ™ technology platform for complex Ophthalmic drug formulations.  The technology innovations brings high added value and significant investment returns.  Its ophthalmic blockbuster product ZENNO-01 is expected to be launched in the United States in 2022. It has signed a 20-year long-term cooperation and exclusive sales agreement in the United States with a leading global ophthalmic drug multinational company.  


Mr. Yali Li pointed out that besides the high potential in US market, China market is very attractive to Zennova Pharma Group too.  China's pharmaceutical industry is undergoing series of upgrades, shifts and structural changes.  It will provide market opportunities to company like Zennova, who has continuous product development and technological innovation.  Zennova Pharmaceutical will continue to leverage capital investment to accelerate the research and development of new products, speedy up the technology of Ophthalmic products, and provide top-quality pharmaceuticals with superior value to patients around the world.